The effect of race/ethnicity on cancer-specific mortality after trimodal therapy
- 20 March 2024
- journal article
- research article
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 12 (3) , 1416-1422
Abstract
Introduction Trimodal therapy (TMT) is the most validated bladder-sparing treatment for organ-confined urothelial carcinoma of the urinary bladder (OC UCUB, namely cT2N0M0). However, it is unknown if barriers to the use of TMT or cancer-specific mortality (CSM) differences exist according to race/ethnicity. We addressed this knowledge gap. Material and methods Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified OC UCUB patients aged from 18 to 85 treated with radical cystectomy (RC) or TMT. Temporal trends described TMT versus RC use over time. Subsequently, in the subgroup of TMT-treated patients, survival analyses consisting of Kaplan–Meier plots and multivariable Cox regression (MCR) models addressed CSM according to race/ethnicity. Results Among 19,501 assessable patients, 15,336 (79%) underwent RC versus 4165 TMT (21%). Overall, of all races/ethnicities, 16,245 (83.3%) were White Americans, 1215 (6.3%) Hispanics, 1160 (5.9%) African Americans, and 881 (4.5%) Asian/Pacific Islanders. Among TMT-treated patients, 3460 (83.1%) were White Americans, 298 (7.1%) African Americans, 218 (5.3%) Hispanics, and 189 (4.5%) Asian/Pacific Islanders. The lowest rate of TMT use relative to RC and TMT patients was recorded in Hispanics (17.9%). Over time, TMT use increased in White Americans (EAPC: + 4.5%, p = 0.001) and Asians/Pacific Islanders (EAPC: + 5.2%, p = 0.003), but not in others. Kaplan–Meier analyses showed median CSM of 49 months, 41 months, and 34 months and not reached in White Americans, Hispanics, African Americans, and Asian/Pacific Islanders, respectively (p = 0.02). In MCR models, two race/ethnicity subgroups independently predicted either worse (African Americans, HR: 1.20, p = 0.02) or better CSM (Asian/Pacific Islanders, HR: 0.75, p = 0.02). Conclusion Race/ethnicity affects both access to TMT (lower access in Hispanics) as well as survival after TMT (better in Asians/Pacific Islanders and worse in African Americans).Keywords
This publication has 24 references indexed in Scilit:
- Epidemiology, Screening, and Prevention of Bladder CancerEuropean Urology Oncology, 2022
- Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicityInternational Urology and Nephrology, 2022
- Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly PatientsClinical Genitourinary Cancer, 2022
- Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvementCancer Causes & Control, 2022
- Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched AnalysisClinical Genitourinary Cancer, 2021
- Disparities in male versus female oncologic outcomes following bladder preservation: A population‐based cohort studyCancer Medicine, 2021
- Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder CancerJAMA Surgery, 2019
- Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race‐based differences in survival?Cancer, 2019
- Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalationJournal of Radiation Oncology, 2017
- Racial variation in the quality of surgical care for bladder cancerCancer, 2013